Rowan E. Chapman Sells 1,767 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

by · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report) Director Rowan E. Chapman sold 1,767 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total transaction of $300,814.08. Following the completion of the sale, the director now directly owns 6,202 shares in the company, valued at approximately $1,055,828.48. The trade was a 22.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $0.67 during trading on Wednesday, reaching $167.12. 735,357 shares of the company traded hands, compared to its average volume of 1,332,419. The firm has a market capitalization of $22.06 billion, a PE ratio of -94.95 and a beta of 1.63. Natera, Inc. has a 52 week low of $56.00 and a 52 week high of $175.63. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average is $142.48 and its two-hundred day moving average is $123.76.

Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the prior year, the business posted ($0.95) earnings per share. Natera’s revenue was up 63.9% compared to the same quarter last year. As a group, sell-side analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Canaccord Genuity Group upped their price objective on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group increased their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Finally, Leerink Partners lifted their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $140.59.

Check Out Our Latest Research Report on Natera

Institutional Trading of Natera

Large investors have recently made changes to their positions in the company. Franklin Resources Inc. lifted its stake in Natera by 42.6% during the third quarter. Franklin Resources Inc. now owns 1,099,335 shares of the medical research company’s stock worth $144,958,000 after purchasing an additional 328,375 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Natera during the 3rd quarter worth $385,000. Sanctuary Advisors LLC lifted its position in shares of Natera by 113.1% during the 3rd quarter. Sanctuary Advisors LLC now owns 7,486 shares of the medical research company’s stock worth $950,000 after buying an additional 3,973 shares during the last quarter. Coldstream Capital Management Inc. acquired a new stake in Natera in the third quarter valued at about $305,000. Finally, Geode Capital Management LLC grew its position in Natera by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after acquiring an additional 143,825 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading